Abstract:Abstract Background Nudix hydrolase 15 (NUDT15) genetic polymorphisms confer an increased risk of thiopurine-induced myelosuppression (TIM). Thiopurines continue to be widely used as maintenance therapy for inflammatory bowel disease (IBD) in patients worldwide. However, the global prevalence of NUDT15 variants and incidence of TIM in IBD remains unclear. We aimed to evaluate the global prevalence of NUDT15 polymorphisms in IBD patients and incidence of thiopurine-induced leukopenia in patients with these polymorphisms. Methods We searched Medline, Embase, Emcare, CINAHL, APA PsycInfo and the Cochrane Library databases from inception until 7 July 2022. Full-text articles and conference abstracts reporting the frequency of any NUDT15 polymorphism and/or frequency of leukopenia in adult IBD patients with these variants, were included. Studies that examined paediatric populations or mixed disease populations, or reported duplicate data, were excluded. A random effects model was performed to estimate the pooled prevalence of NUDT15 variants, pooled prevalence of early (≤8 weeks) and late (>8 weeks) leukopenia and relative risk (RR) of developing leukopenia. Results 20 studies comprising 5232 IBD patients were included. The pooled prevalence of the *1/*1 wild type genotype was 83% (95% CI: 0.78-0.88). The pooled prevalence of the *1/*3 c.415C>T C/T variant was 13% (95% CI: 0.10-0.18), *3/*3 c.415C>T T/T variant was 2% (95% CI: 0.01-0.02), *1/*5 c.52G>A G/A variant was 2% (95% CI: 0.01-0.03) and *1/*6 c.36_37insGGAGTC ins/- variant was 7% (95% CI: 0.04-0.12). Subgroup analyses showed a higher pooled prevalence of the *1/*3 c.415C>T C/T variant in Japanese (20%, 95% CI: 0.16-0.24) and Chinese patients (18%, 95% CI: 0.12-0.27). Patients with the *1/*3 c.415C>T C/T variant had a RR of 4.12 (95% CI: 2.87-5.91) of developing leukopenia relative to the *1/*1 genotype, and the pooled prevalence of early leukopenia was 20% (95% CI: 0.16-0.26) and late leukopenia was 36% (95% CI: 0.26-0.49). Patients with the *3/*3 c.415C>T T/T variant had a RR of 9.38 (95% CI: 5.17-17.01) of developing leukopenia relative to the *1/*1 genotype, and the pooled prevalence of early leukopenia was 99% (95% CI: 0.07-1.00). The pooled prevalence of early leukopenia was 49% (95% CI: 0.29-0.69) in patients with the *1/*6 c.36_37insGGAGTC ins/- variant. Conclusion NUDT15 polymorphisms are common in IBD patients and strongly predict thiopurine-induced leukopenia. The most common variant was the *1/*3 c.415C>T C/T variant and the *3/*3 c.415C>T T/T variant was associated with the highest risk of leukopenia. Pre-treatment genotyping for NUDT15 variants should be considered particularly in Asian populations, to guide individualised thiopurine dosing and avoid myelotoxicity.

Advances in genetic polymorphism of NUDT15 and leucopenia caused by thiopurines

P096 Combined Detection Variants of NUDT15 Could Highly Predict Thiopurine-Induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: a Multi-Center Analysis

Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: A Multicenter Analysis

NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients.

Impact Of Nudt15 Polymorphisms On Thiopurines-Induced Myelotoxicity And Thiopurines Tolerance Dose

NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients with Autoimmune Hepatitis and Related Cirrhosis

NUDT15 Polymorphisms Are Better Than Thiopurine S‐methyltransferase As Predictor of Risk for Thiopurine‐induced Leukopenia in Chinese Patients with Crohn's Disease

P440 Prevalence of NUDT15 polymorphisms and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease patients: A systematic review and meta-analysis

Comparison of and polymorphisms in Chinese patients with inflammatory bowel disease.

Inosine Triphosphate Pyrophosphatase and NUDT15 Are Good Predictors of Clinical Outcomes in Thiopurine-Treated Chinese Patients with Inflammatory Bowel Disease.

P469 Effectiveness of Dose Optimisation by Pre-Genotyping NUDT 15 R139C on Reducing Thiopurine-Induced Leucopoenia in Chinese Patients with Crohn’s Disease: a Randomised Controlled Trial

NUDT15 R139C variation increases the risk of azathioprine-induced toxicity in Chinese subjects: Case report and literature review.

NUDT15 R139C Variation Increases the Risk of Azathioprine-Induced Toxicity in Chinese Subjects

NUDT15 Genetic Variants in Chinese Han, Uighur, Kirghiz, and Dai Nationalities

Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.

Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis

Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease

Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients

[Relationship Between Single Nucleotide Polymorphisms in Thiopurine Methyltransferase Gene and Tolerance to Thiopurines in Acute Leukemia].

Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn’s disease who turned out to possess homozygous mutations in NUDT15 R139C